It appears that the IMET story is breathing new life into the PPS as ASH abstracts approach. A few favorable abstracts could work wonders. We will soon know.
So far, there is no negative news concerning IMET, as ASH abstracts approach. Geron seems to be slowing waking up, as the hedge fund shorts lose control (I hope). These controlled markets were explained in a recent Washington Post article (on this board). IMET & Mayo will be the dominating medical factors.
There is no way that IMET can get high marks at ASH (A or A+) and not have the PPS go higher. It could be the merged company with Geron gone, Geron with a new partner, or Geron stlll intact. With any combination, IMET at ASH will have a significant impact for investors and patients.
The tug-of-war concerning the PPS will be resolved at ASH. The ASH abstracts (and other symposiums) will start the ball rolling. As far as I can tell, the ASH exposure will be very positive for IMET.
I believe that all the IMET evidence at ASH will be positive. No one claims otherwise, as far as I know, in the medical community. Yet the tug-of-war continues with the hedge funds still in control of the PPS. There has been every view expressed on this board about: (1) How this is possible? (2) Why the FDA is complicit? I don't know the answers, and we can all have opinions. I believe that it will turn out (at ASH and in other symposiums) that IMET is a fine drug, that works, is safe, and has considerable potential. Most of us already believe that, but we need additional verification. It will start, IMO, with the ASH abstracts.
The FDA has to have a reason to maintain the residual hold, but none is apparent. The residual hold has no medical meaning, and needs to disappear. ASH will be the "informer".
Verifying what we "think" we know would be great. We think that Mayo is honest, efficient, and correct about the "miracle" properties of Imetelstat. The problem is that most of the investing world does not believe their results for one reason or another. ASH, I hope, will bring these out the "truth", and that should be very positive for investors and patients. There is always that feeling that something "bad" has been missed, but it is nowhere in sight. ASH should be a positive experience for all IMET supporters. ASH abstracts are almost here (Nov. 6).
There is nothing to hold IMET back; No significant side effects, Works, Unique. Spike in price near & connected to ASH abstracts.
A paralysed man has been able to walk again after a pioneering therapy that involved transplanting cells from his nasal cavity into his spinal cord.
Darek Fidyka, who was paralysed from the chest down in a knife attack in 2010, can now walk using a frame.
The treatment, a world first, was carried out by surgeons in Poland in collaboration with scientists in London.
“I have waited 40 years for something like this”
Prof Wagih El Masri
Consultant spinal injuries surgeon
(Details of the research are published in the journal Cell Transplantation.)
Darek Fidyka, 40, from Poland, was paralysed after being stabbed repeatedly in the back in the 2010 attack.
He said walking again - with the support of a frame - was "an incredible feeling", adding: "When you can't feel almost half your body, you are helpless, but when it starts coming back it's like you were born again."
Prof Geoff Raisman, chair of neural regeneration at University College London's Institute of Neurology, led the UK research team.
He said what had been achieved was "more impressive than man walking on the moon".
I am looking for the IMET negatives. I see no significant side-effects, and no claim from Mayo (MF studies) or anyone else that IMET does not work. The FDA has no reason to keep IMET off of the market, and out of the hands of needy patients. The conclusion has to be that the FDA is on Mayo's and IMET's side, and Mayo is calling the "shots". ASH will tell all.
The FDA has no creditable medical or scientific reasons for any hold that involves IMET and liver-functions. The FDA, as an honest broker, having used an "abundance of caution", is about to release the last vestiges of any such hold. ASH will see to that. Very positive news about IMET will start with the ASH abstracts.
I wasn't aware of these foreign trials (Germany, Switzerland) and the apparent successes (recent posts) for IMET. It is often the case that approvals are granted in Europe before the USA. Perhaps that has been the plan all along. Novartis and Roche have important blood cancer programs
There is really nothing to do now, but wait for ASH news. ASH will make or break IMET (make, I think). Geron's PPS will reflect this, but Geron has its own identity that is separate from IMET. Geron will be merged out of existence, or team-up with a powerful partner, most likely.
There is a timely convergence taking place between ASH abstracts, and the repair of the FDA-Mayo-Geron problems caused by the low level-liver-considerations (holds). The market is taking note. In addition the telomere-telomerase bond has potential well beyond the MF successes. There is potential in combination drugs (Amgen, Yale) and in pediatric tumors (NCI) and pancreatic cancers.
There is a timely convergence taking place between ASH abstracts, and the repair of the FDA-Mayo-Geron problems caused by the low level-liver-considerations (holds). The market is talking note. In addition the telomere-telomerase bond has potential well beyond the MF successes.
Everything looks positive for IMET. ASH abstracts (Nov. 6) and ASH (Dec. 6) will tell us all we need to know about the current science and medical progress. The "Geron-story" is still being written. Thanks again for the upbeat summery.
"Telomeres–the terminal caps of chromosomes–become shorter as individuals age, and there is much interest in determining what causes telomere attrition since this process may play a role in biological aging. The leading hypothesis is that telomere attrition is due to inflammation, exposure to infectious agents, and other types of oxidative stress, which damage telomeres and impair their repair mechanisms. Several lines of evidence support this hypothesis, including observational findings that people exposed to infectious diseases have shorter telomeres. Experimental tests are still needed. "